Division of Orthopaedic Surgery, Department of Surgery, Queen's University, Kingston, ON, Canada.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
J Orthop Trauma. 2024 Sep 1;38(9):e325-e332. doi: 10.1097/BOT.0000000000002848.
To evaluate the patient-reported expectations regarding cannabis for pain following musculoskeletal (MSK) trauma and patients' perceptions and attitudes regarding its use.
A cross-sectional retrospective survey-based study.
Three orthopaedic clinics in Ontario (Level-1 trauma center, Level-2 trauma center, rehabilitation clinic).
Adult patients presenting to the clinics from January 24, 2018, to March 7, 2018, with traumatic MSK injuries (fractures/dislocations and muscle/tendon/ligament injury) were administered an anonymous questionnaire on cannabis for MSK pain.
Primary outcome measure was the patients' perceived effect of cannabis on MSK pain, reported on a continuous pain scale (0%-100%, 0 being no pain, and 100 unbearable pain). Secondary outcomes included preferences, such as administration route, distribution method, timing, and barriers (lack of knowledge, concerns for side effects/addiction, moral/religious opposition, etc.) regarding cannabis use.
In total, 440 patients were included in this study, 217 (49.3%) of whom were female and 222 (50.5%) were male, with a mean age of 45.6 years (range 18-92 years, standard deviations 15.6). Patients estimated that cannabis could treat 56.5% (95% CI 54.0%-59.0%) of their pain and replace 46.2% (95% CI 42.8%-49.6%) of their current analgesics. Nearly one-third (131/430, 30.5%) reported that they had used medical cannabis and more than one-quarter (123/430, 28.6%) used it in the previous year. Most felt that cannabis may be beneficial to treat pain (304/334, 91.0%) and reduce opioid use (293/331, 88.5%). Not considering using cannabis for their injury (132/350, 37.7%) was the most common reason for not discussing cannabis with physicians. Higher reported pain severity (β = 0.2/point, 95% CI 0.1-0.3, P = 0.005) and previous medical cannabis use were associated with higher perceived pain reduction (β = 11.1, 95% CI 5.4-16.8, P < 0.001).
One in 3 orthopaedic trauma patients used medical cannabis. Patients considered cannabis could potentially be an effective option for managing traumatic MSK pain and believed that cannabis could reduce opioid usage following acute musculoskeletal trauma. These data will help inform clinicians discussing medical cannabis usage with orthopaedic trauma patients moving forward.
评估肌肉骨骼(MSK)创伤后患者对大麻治疗疼痛的预期以及他们对大麻使用的看法和态度。
一项基于横断面回顾性调查的研究。
安大略省的 3 个骨科诊所(1 级创伤中心、2 级创伤中心、康复诊所)。
2018 年 1 月 24 日至 3 月 7 日,因创伤性 MSK 损伤(骨折/脱位和肌肉/肌腱/韧带损伤)就诊于诊所的成年患者接受了一项关于大麻治疗 MSK 疼痛的匿名问卷。
主要结局指标为患者对大麻治疗 MSK 疼痛的感知效果,通过连续疼痛量表(0%-100%,0 表示无痛,100 表示无法忍受的疼痛)报告。次要结局指标包括对大麻使用的偏好,如给药途径、分配方法、时间安排以及(缺乏知识、对副作用/成瘾的担忧、道德/宗教反对等)障碍。
本研究共纳入 440 例患者,其中 217 例(49.3%)为女性,222 例(50.5%)为男性,平均年龄为 45.6 岁(18-92 岁,标准差 15.6)。患者估计大麻可以治疗 56.5%(95%CI 54.0%-59.0%)的疼痛,替代 46.2%(95%CI 42.8%-49.6%)的当前镇痛药。近三分之一(131/430,30.5%)的患者报告曾使用医用大麻,超过四分之一(123/430,28.6%)的患者在过去一年中使用过。大多数人认为大麻可能有助于治疗疼痛(304/334,91.0%)并减少阿片类药物的使用(293/331,88.5%)。不考虑将大麻用于治疗他们的损伤(132/350,37.7%)是患者未与医生讨论大麻的最常见原因。报告的疼痛严重程度较高(β=0.2/分,95%CI 0.1-0.3,P=0.005)和以前使用过医用大麻与较高的疼痛缓解感知相关(β=11.1,95%CI 5.4-16.8,P<0.001)。
三分之一的骨科创伤患者使用医用大麻。患者认为大麻可能是治疗创伤性 MSK 疼痛的有效选择,并认为大麻可以减少急性肌肉骨骼创伤后的阿片类药物使用。这些数据将有助于为今后与骨科创伤患者讨论医用大麻使用的临床医生提供信息。